Company intelligence / Profile preview
ITM Isotope Technologies Munich SE
Garching / Munich, Bavaria, Germanyitm-radiopharma.com ↗
- Ownership
- Private
- Employees
- ~750
- Development stage
- Other
01
Overview
ITM-11 (n.c.a. ¹⁷⁷Lu-edotreotide) NDA accepted by FDA with PDUFA date August 28, 2026 for GEP-NETs; ITM-94 received FDA Fast Track for diagnostic in clear cell renal cell carcinoma, forming theranostic pair with ITM-91.
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TemasekBlackRockQatar Investment AuthorityCanadian Nuclear Laboratories (joint venture)
Beyond the preview
Go deeper on ITM Isotope Technologies Munich SE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITM Isotope Technologies Munich SE.